Article Text

Download PDFPDF

LO-031 Working towards a core minimal dataset for systemic lupus erythematosus studies
  1. Stephen Mcdonald1,
  2. Jialin Teng1,2,
  3. Michelle Barraclough1,3 and
  4. Ian Bruce1,3
  1. 1The Kellgren Centre for Rheumatology, NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, UK
  2. 2Department of Rheumatology and Immunology, Ruijin Hospital, Tong University School of Medicine, Shanghai, China
  3. 3Centre for Epidemiology Versus Arthritis, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK


Background Systemic Lupus Erythematosus (SLE) is a complex autoimmune disease and its heterogeneity means that many cohorts and clinical trials do not collect the same data, making comparative studies difficult. We aimed to ascertain what data is commonly collected in SLE registries/trials. Our ultimate goal is to generate a core minimal dataset for future SLE studies.

Methods We designed and distributed a questionnaire to members of the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) as well as additional research active centres in China. Our survey included 26 questions about the types of data that are routinely collected for research. Data collected by ≥ 75% of participating centres was used as a threshold for concordance.

Results Eighteen centres; eight from USA/Canada, five from China and five from Europe responded. Table 1 shows the data that ≥ 75% centres collected. Notably, the EULAR/ACR 2019 criteria was collected by 33.3% and even the most commonly collected patient reported outcome (PRO) – the SF36, was only collected by 53.3%. The SLICC/ACR SLE damage index did not reach our threshold (68.4%). Current treatment data collected did include drug name, dose, frequency and start date. Previous treatment reason for cessation was collected only pertaining to antimalarials. Baseline anti-dsDNA (ELISA) and Crithidia were collected by 70.6% and 52.9% respectively and baseline immunoglobulins were measured by 70.6%. Follow-up blood counts and complement C3/4 were collected by ≥ 75% of centres.

Conclusions An initial set of commonly collected data was identified. This forms the basis to start to consider a core minimum dataset for SLE. Development and further refinement of this dataset is needed, as will common definitions of each data field to allow widespread use.

Abstract LO-031 Table 1

Data that ≥ 75% centres collected

  • Research
  • Clinical Trials

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.